Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors.

Lucot JB, Brame RE, Garrett TL, Pfadenhauer EH, Kumar A, Fick DB, Helton DR.

Exp Brain Res. 2014 Aug;232(8):2699-707. doi: 10.1007/s00221-014-4004-z. Epub 2014 Jun 10.

PMID:
24913143
2.

Urotensin II acts as a modulator of mesopontine cholinergic neurons.

Clark SD, Nothacker HP, Blaha CD, Tyler CJ, Duangdao DM, Grupke SL, Helton DR, Leonard CS, Civelli O.

Brain Res. 2005 Oct 19;1059(2):139-48. Epub 2005 Sep 23.

PMID:
16183039
3.

Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone.

Helton DR, Osborne DW, Pierson SK, Buonarati MH, Bethem RA.

Drug Metab Dispos. 2000 Aug;28(8):925-9.

PMID:
10901702
4.

LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats.

Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ.

Neuropharmacology. 1997 Nov-Dec;36(11-12):1511-6.

PMID:
9517421
5.

Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.

Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ.

J Pharmacol Exp Ther. 1998 Feb;284(2):651-60.

PMID:
9454811
6.

2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.

Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M.

J Med Chem. 1998 Jan 29;41(3):358-78.

PMID:
9464367
7.

Serotonin-1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response.

Rasmussen K, Kallman MJ, Helton DR.

Synapse. 1997 Oct;27(2):145-52.

PMID:
9266775
8.

Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.

Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD.

J Med Chem. 1997 Feb 14;40(4):528-37.

PMID:
9046344
9.

LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.

Iyengar S, Hipskind PA, Gehlert DR, Schober D, Lobb KL, Nixon JA, Helton DR, Kallman MJ, Boucher S, Couture R, Li DL, Simmons RM.

J Pharmacol Exp Ther. 1997 Feb;280(2):774-85.

PMID:
9023291
10.

The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle.

Rasmussen K, Czachura JF, Kallman MJ, Helton DR.

Neuroreport. 1996 Apr 10;7(5):1050-2.

PMID:
8804049
11.

Central nervous system characterization of the new cholecystokininB antagonist LY288513.

Helton DR, Berger JE, Czachura JF, Rasmussen K, Kallman MJ.

Pharmacol Biochem Behav. 1996 Mar;53(3):493-502.

PMID:
8866946
12.

General pharmacology of insulin lispro in animals.

Helton DR, Zimmermann JL, Heim A, Jones TW, Turk JA, Kallman MJ.

Arzneimittelforschung. 1996 Jan;46(1):91-7.

PMID:
8821525
14.

The CCK-B antagonist LY288513 blocks diazepam-withdrawal-induced increases in auditory startle response.

Rasmussen K, Helton DR, Berger JE, Scearce E.

Ann N Y Acad Sci. 1994 Mar 23;713:374-6. No abstract available.

PMID:
8185192
15.

The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.

Rasmussen K, Helton DR, Berger JE, Scearce E.

Neuroreport. 1993 Nov 18;5(2):154-6.

PMID:
8111002
16.

Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists.

Tizzano JP, Griffey KI, Johnson JA, Fix AS, Helton DR, Schoepp DD.

Neurosci Lett. 1993 Nov 12;162(1-2):12-6.

PMID:
8121613
17.

Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity.

Helton DR, Modlin DL, Tizzano JP, Rasmussen K.

Psychopharmacology (Berl). 1993;113(2):205-10.

PMID:
7855182
18.

Behavioral characterization of the new potent nonselective dopamine agonist pergolide.

Helton DR, Modlin DL, Williams PD.

Arzneimittelforschung. 1992 Jul;42(7):885-90.

PMID:
1418051
19.

The proconvulsive activity of quinolone antibiotics in an animal model.

Williams PD, Helton DR.

Toxicol Lett. 1991 Sep;58(1):23-8.

PMID:
1897004
20.

General pharmacology of a new potent 5-hydroxytryptamine antagonist.

Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH.

Arzneimittelforschung. 1991 Mar;41(3):189-95.

PMID:
1867653

Supplemental Content

Loading ...
Support Center